Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

The American College of Radiology advises women who are at average risk for breast cancer to get mammograms annually starting ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer.

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Current and past smokers are being offered lung checks as part of an NHS programme to catch cancer early. Invites are being sent to more than 10,000 people in Scunthorpe, aged between 55 and 74, as ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...

Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult ...

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...

A lawsuit against Fairmont State University alleges that a former student developed lung cancer because she was exposed to asbestos on the campus.